共 50 条
- [24] Cost-effectiveness of voretigene neparvovec in the treatment of patients with inherited retinal disease with RPE65 mutation in Switzerland BMC Health Services Research, 22
- [26] Retinal Pigment Epithelium Atrophy After Subretinal Voretigene Neparvovec-rzyl for RPE65-Related Disease: A 6-Month Follow-Up RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2022, 42 (12): : E55 - E56
- [27] Five-year update for the Phase III voretigene neparvovec study in biallelic RPE65 mutation-associated inherited retinal disease CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2022, 49 (08): : 966 - 967